TuHURA BIOSCIENCES, INC./NV Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
TuHURA BIOSCIENCES, INC./NV (HURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.04% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.86%, a 17.17% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.66%, a 4.70% decline year-over-year.
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.89%.
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.66%, a 7.13% increase from fiscal 2024.
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.35%, a 11.04% decline from fiscal 2023.
- TuHURA BIOSCIENCES, INC./NV share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.89%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.04% 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 3.86% 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 4.66% 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 4.66% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 4.66% 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | 4.66% 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | 4.35% 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 4.89% 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 4.89% 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | 4.89% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 4.89% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |